Establishment Labs (ESTA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Supplement corrects a typographical error in the previously disclosed 2025 non-employee director compensation table, updating stock award values and total compensation for several directors.
Revised compensation figures reflect accurate stock and option awards, as well as cash or share-based fee payments for each director.
Voting matters and shareholder proposals
All previously submitted proxies and voting instructions remain valid for the 2026 Annual General Meeting; shareholders may change or revoke votes as described in the proxy materials.
Shareholders are encouraged to vote prior to the meeting using the methods outlined in the proxy statement.
Board of directors and corporate governance
Compensation details provided for each non-employee director, including cash fees, stock awards, and option awards for 2025.
Dennis Condon served on the board until his passing in January 2025.
Juan José Chacón Quirós ended non-director employment in April 2025 but continues as a non-employee director and consultant.
Latest events from Establishment Labs
- 2025 guidance targets $205–$210M revenue, EBITDA positive, and rapid US-driven growth.ESTA
Investor Day 20259 Jul 2026 - Rapid U.S. growth, premium pricing, and innovation set the stage for market dominance and expansion.ESTA
TD Cowen 46th Annual Health Care Conference8 Jul 2026 - Q4 revenue up 45%, gross margin at 70.5%, and 2026 revenue growth guided above 25%.ESTA
Q4 20258 Jul 2026 - All proposals passed with majority approval and no shareholder questions were raised.ESTA
AGM 202628 May 2026 - Q1 revenue up 45% year-over-year, gross margin at 70.7%, and 2026 guidance raised.ESTA
Q1 20268 May 2026 - Virtual meeting to elect directors, approve pay, and ratify auditor, with strong governance focus.ESTA
Proxy filing10 Apr 2026 - Vote on directors, executive pay, and auditor ratification at the May 2026 annual meeting.ESTA
Proxy filing10 Apr 2026 - Q2 revenue rose 18.7% sequentially; FDA approval for Motiva Implants expected soon.ESTA
Q2 20242 Feb 2026 - Innovation, global expansion, and regulatory progress position the company for rapid growth.ESTA
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026